Most regenerative medicine clinic owners are stuck between two bad outcomes. They either say too much in their marketing and risk FDA or FTC enforcement, or they say nothing and lose patients to competitors who are marketing aggressively. The traffic light framework ends the guessing game. Red means never publish. Yellow means use it only with specific framing and disclaimers. Green means you can use it with confidence. This is the system that replaces paralysis with precision.
TLDR: This guide gives regenerative medicine clinic owners a clear, modality-by-modality language system for compliant marketing. Red light language (disease cure claims, guaranteed outcomes, FDA misrepresentations) can never appear in your marketing under any circumstance. Yellow light language (research framing, off-label disclosures, patient experience statements) is allowed only with specific disclaimers and structure. Green light language (educational overviews, process descriptions, consultation CTAs) is safe and effective. The framework covers stem cells, exosomes, PRP and PRF, and peptides, with specific examples for each.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm.
I have been in this industry since 2015, and the compliance conversation is always the same. The clinic owner says, “I know I can’t say ‘cure,’ but what CAN I say?” Then they hand me their website copy, and half of it is in the red zone without them knowing it. The other half is so vague it does not say anything at all.
Neither extreme works. Reckless marketing gets you a warning letter. We covered exactly what that looks like in our guide on FDA warning letters and regenerative medicine marketing. But silent marketing gets you nothing: no patients, no growth, no practice.
The traffic light framework fixes this. It gives you and your marketing team a decision system you can apply to every piece of content before it goes live. Every website page, every social media post, every email, every ad. Red, yellow, or green. Here is how it works.
Why Regen Marketing Is Different From Every Other Industry
In most industries, marketing language is a branding decision. In regenerative medicine, marketing language is a regulatory decision.
Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), the intended use of a product determines its legal classification. And intended use is established by how you market it. The moment your website says a product “treats,” “cures,” “heals,” or “prevents” a disease, you have legally reclassified that product as an unapproved drug or biologic. This is true regardless of what the product actually is or how it is used clinically.
Think of it this way. Your marketing is like a delivery truck. The truck delivers information about your practice: who you are, what you offer, and how patients can learn more. That is legal. But the moment your delivery truck starts carrying therapeutic promises (“this product heals your joints”), it has crossed into drug promotion territory. You are no longer marketing a practice. You are marketing an unapproved drug.
The FDA’s framework for regulation of regenerative medicine products makes this clear. A cell or tissue product (an HCT/P) gets the lighter Section 361 path only if it meets all four criteria in 21 CFR 1271.10(a). That is an exemption the product earns, not a label you pick. Otherwise it is a Section 351 biologic that needs FDA approval. PRP is a different case. It is a blood component, not an HCT/P, so the 361 test does not apply to it. Classification follows the regulation, not your wording. But your claims are evidence of intended use, and a claim to treat disease can make any product an unapproved drug or biologic.
This is the concept most clinic owners have never been taught. The words you choose become evidence of what your product is for. Our 361 vs. 351 guide walks through the four criteria.
What this means for your practice: Every word on your website, social media, and marketing materials carries regulatory weight. The traffic light framework gives you a system to make those word choices correctly, every time.
The Three Tiers: Red, Yellow, and Green
The framework is simple to understand and immediate to apply.
Red light means never publish, under any circumstance, on any platform, in any format. These phrases trigger FDA enforcement, FTC penalties, or both. There are no exceptions and no workarounds.
Yellow light means the language is allowed, but only with specific framing, disclaimers, and structure. Remove the framing, and yellow becomes red. Every yellow-light phrase has required conditions attached to it.
Green light means you can use this language with confidence. These are the approved patterns that attract patients, build trust, and stay fully compliant. This is where your marketing should live most of the time.
The goal is not to memorize every rule. The goal is to train your instinct. Before publishing any content, ask: is this red, yellow, or green? If you are not sure, treat it as red until you verify.
Red Light Language: What You Must Never Say
These phrases are prohibited across all platforms: website, social media, email, ads, Google Business Profile, printed materials, and video content. The FTC’s Health Products Compliance Guidance and the FD&C Act apply to all of them.
Stem Cells
| Red Light (Never Use) | Why It Is Prohibited |
|---|---|
| “Stem cells cure arthritis” | Unapproved drug/biologic claim under FD&C Act |
| “Stem cell therapy reverses aging” | Unapproved disease/condition treatment claim |
| “FDA-approved stem cell therapy” (for any use the FDA has not approved) | Misrepresentation of FDA status; deceptive under FTC |
| “Stem cells regrow cartilage” | Unapproved biologic efficacy claim |
| “Stem cell facelift reverses aging” | Disease/condition treatment claim for unapproved product |
Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications.
Exosomes
| Red Light (Never Use) | Why It Is Prohibited |
|---|---|
| “Exosome therapy heals [anything]” | No FDA-approved exosome products exist for any human medical use |
| “Exosomes regrow cartilage” | Unapproved biologic efficacy claim |
| “Book your exosome treatment” | Marketing an unapproved product as an available treatment |
| “Exosomes reverse aging” | Disease/condition treatment claim; no approval exists |
There are zero FDA-approved exosome products for human therapeutic use. Any marketing that positions exosomes as a treatment violates federal law. The FDA’s consumer alert on regenerative medicine products specifically warns about this.
PRP and PRF
| Red Light (Never Use) | Why It Is Prohibited |
|---|---|
| “PRP cures joint pain” | Disease cure claim for off-label use |
| “FDA-approved PRP for hair loss” | Misrepresentation; PRP devices are 510(k) cleared for bone graft handling only |
| “PRP heals your knees” | Disease treatment claim for unapproved indication |
PRP devices are cleared for a single use: bone graft handling. Everything else (joints, hair, aesthetics) is off-label. You cannot market an off-label use as if it were approved.
Peptides
| Red Light (Never Use) | Why It Is Prohibited |
|---|---|
| “BPC-157 heals tendons” | Benefit claim; BPC-157 is not FDA approved for any use, and no peptide may carry a benefit claim |
| “Peptide therapy cures [anything]” | No approved therapeutic peptide products for these claims |
| “We offer BPC-157 injections” | Red as written. BPC-157 has a narrow path under the October 2026 HHS policy, but only with every control listed below. Peptides outside the six are never offered. |
On October 30, 2026, HHS published an interim policy for six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. A licensed 503A pharmacy may compound them, one at a time, on an individual prescription, when ten conditions are met. It is not FDA approval, it does not put them on the 503A bulks list, and HHS may revisit it. Every other peptide stays outside it.
That policy came after a busy year. The FDA took a group of popular peptides off its Category 2 list on April 22, 2026. An FDA advisory committee reviewed seven of them in July 2026 and recommended six.
For a clinic page, the rules stay tight. No peptide gets a benefit, recovery or anti-aging claim. Only the six may carry an availability line. That line needs the pharmacy’s written confirmation of all ten conditions and the compounded peptide notice right beside it. It also needs no stack, no paid ads, counsel confirming the state board’s position, and a date on the page. Every other peptide gets education and status only. Our peptide marketing rules walk through the full check.
Universal Red Light Language
| Red Light (Never Use) | Why It Is Prohibited |
|---|---|
| “Guaranteed results” / “100% effective” | Impossible to substantiate per FTC requirements |
| “Completely safe, no side effects” | Impossible to substantiate; hides material risk |
| “Better than surgery” | Requires high-grade comparative clinical data |
| “Our patients are cured” | Testimonial with disease cure claim for unapproved product |
In January 2025, the FTC banned the co-founders of a stem cell company from marketing stem cell treatments. The case involved deceptive claims, including testimonials with unapproved treatment claims. This is real enforcement with real consequences.
What this means for your practice: If any of these phrases appear anywhere in your marketing right now, remove them today. Do not wait. The FDA and FTC are actively enforcing, and ignorance is not a defense.
Yellow Light Language: How to Use It Correctly
Yellow light language is allowed, but only with specific structure. The formula is: a conditional phrase, plus the evidence and the off-label or research disclosure, plus a consult invite that sits apart from any condition name. Remove any part of the formula, and yellow becomes red. Stem cell and exosome education is the exception. It gets no consult invite next to it at all.
Research Framing
“Some studies suggest PRP may support symptom management in mild-to-moderate knee osteoarthritis [link to the published studies]. The evidence is limited [name the evidence grade]. PRP devices are FDA cleared for handling bone graft material. Using PRP for joints is off-label, and the FDA has not evaluated it for that use. Individual results vary.”
Every element matters. The link shows where the evidence comes from, and the grade says how strong it is. “May support” is still a claim, so it needs that evidence behind it. Hedging is not a defense, and for cord, placental or exosome products hedged words are red light. “Individual results vary” is the FTC typicality disclosure. The cleared use, the off-label line and the not-evaluated-by-FDA line are the regulatory disclosure. Keep the consult invite in its own paragraph, away from the condition name.
Research Commentary
“A [year] study in [journal, linked] looked at PRP in knee osteoarthritis. The authors said more research is needed. PRP for joint use is off-label, and the FDA has not evaluated it for that use.” Commentary like this is yellow light, not green. It needs the link, the evidence grade, the off-label line and the not-evaluated-by-FDA line.
Off-Label Use Disclosure
“Some clinicians use PRP for hair restoration. This is considered an off-label use. PRP devices are cleared by the FDA for bone graft handling. Schedule a consultation to discuss your options.”
This works because it accurately describes clinical practice, clearly labels the use as off-label, states the actual approved indication, and routes to a consultation rather than a treatment booking.
Patient Experience Statements
“Some patients report improvement in joint comfort after their consultation and treatment plan.” This must reflect real patient data, include a typicality disclosure (“Results may vary”), and never guarantee outcomes.
Stem Cell Education
“Stem cell research is exploring potential applications in joint health. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications.”
There is no consult invite on purpose. Stem cell education gets no treatment call to action next to it. If you practice in Florida, Utah, Tennessee, Vermont, Washington or Georgia, the ad needs your state’s notice word for word.
Exosome Education
“Exosomes are small vesicles involved in cell-to-cell communication. There are currently no FDA-approved exosome products for human therapeutic use. Any clinical use is investigational.”
What this means for your practice: Yellow light language lets you discuss your services without making prohibited claims. But the disclaimers and framing are not optional. They are the difference between compliant education and illegal promotion.
Green Light Language: What You Can Say With Confidence
This is where your marketing should live most of the time. Green light language attracts patients, builds trust, and carries minimal compliance risk.
Educational overviews. “What is PRP?” “How does regenerative medicine work?” “What are stem cells?” These describe mechanisms and processes without making treatment claims. They are safe, effective for SEO, and position your practice as an authority.
Process descriptions. “During a PRP consultation, we draw a small sample of blood and process it to concentrate platelets. The procedure typically takes about 45 minutes.” Neutral, factual, no outcome promise.
Consultation CTAs. “Schedule a consultation to see if this option may be appropriate for you.” “Interested in learning more? We’d love to start a conversation.” These invite the next step without promising a treatment or outcome.
General wellness framing. “Supports your body’s natural healing processes” fits supplements and general wellness products only, with no disease or condition named. A supplement page also needs the DSHEA disclaimer. Never use it on a stem cell, exosome, tissue or PRP page. For cord, placental or exosome products, “supports,” “promotes” and “may aid” are red light. Hedging is not a defense (FDA warning letter, October 13, 2026).
Trust signals. Physician credentials, certifications, years of experience, professional affiliations. These build E-E-A-T signals for Google and trust signals for patients.
Balanced risk language. “Like any medical procedure, there are potential risks and benefits to discuss with your provider.” This is not just compliant. It builds trust by showing your practice is transparent.
Clinic and team content. “Meet Dr. [Name], a regenerative medicine physician with 15 years of experience.” “Our team is committed to personalized care plans based on individual needs.” No claims needed. Authenticity sells.
What this means for your practice: You have more compliant language options than you think. Green light content is not weak. It is professional, credible, and effective. Patients choose clinics that sound trustworthy, not clinics that sound like infomercials.
How to Apply This to Your Website, Ads, and Social Media
Website service pages. Every service page should lead with education (green light), include regulatory context where appropriate (yellow light with proper framing), and close with a consultation CTA (green light). Exosomes are the exception: education pages only, with no service page and no consult invite. Stem cell education gets no consult invite beside it either. Run every headline, subheading, and paragraph through the traffic light filter before publishing. Your content creation strategy should build these pages systematically.
Google Ads. Most regenerative medicine modalities cannot be advertised directly through Google Ads. Google’s policy on speculative and experimental treatments names stem cell therapy, cellular therapy, gene therapy and PRP, and exosomes fall under the same general ban. Use organic SEO to capture the search demand that paid ads cannot reach.
Social media. Instagram captions, LinkedIn posts, and Facebook content are all public marketing material. The same red/yellow/green rules apply. Educational content, behind-the-scenes posts, and team spotlights are green light. Treatment outcome claims are red light regardless of the platform.
Email subject lines and body copy. Never use red light language in a subject line. “Stem cell cure for knee pain” in an email subject line is the same violation as on a website. Keep email content educational and route to consultations.
Google Business Profile. Your business description, posts, and review responses are marketing content. The traffic light framework applies to all of them.
The Self-Audit Checklist
Before publishing any piece of marketing content, run it through these six questions.
Does this content claim a product treats, cures, heals, reverses, or prevents a disease or condition? If yes, it is red light. Rewrite it.
Does this content describe any use as “FDA approved” when it is not? If yes, it is red light. Remove the claim.
Does this content include patient testimonials with treatment outcome claims for unapproved therapies? If yes, it is red light. Remove the outcome language or replace with experience-based framing.
Does this content include off-label or research language without the required disclaimers? If yes, it is yellow light missing its required framing. Add the disclaimers or rewrite as green light.
Does this content promote stem cell therapy in a state with a notice law? Florida, Utah, Tennessee, Vermont, Washington and Georgia require their statutory notice, word for word, in every ad. In Florida, Tennessee, Georgia, Vermont and Washington, the notice can be no smaller than the largest type in the ad. Tennessee’s law also covers other regenerative medicine therapies. California requires an office posting and a written notice, and Wyoming allows ads only when every condition of its law is met. If yes, add your state’s notice before you publish. Our guide to state stem cell marketing laws has the details.
Does this content describe a process, invite a consultation, or educate without promising an outcome? If yes, it is green light. Publish it.
Always consult qualified legal counsel for compliance questions specific to your practice and state. This framework is educational, not legal advice.
Frequently Asked Questions
What Is the Traffic Light Framework for Regen Clinic Marketing?
It is a three-tier language classification system. Red light language (disease cure claims, guaranteed outcomes, FDA misrepresentations) must never appear in your marketing. Yellow light language (research framing, off-label disclosures) is allowed only with specific disclaimers. Green light language (education, process descriptions, consultation CTAs) is safe and effective.
Can I Talk About Specific Conditions Like Arthritis or Knee Pain in My Marketing?
You can mention conditions in an educational context. An article on “What is osteoarthritis?” is green light when it stays education. Keep it free of links or calls to action for an unapproved product, because context can turn education into a treatment claim. “Our treatment cures osteoarthritis” is red light. The difference is whether you are educating about a condition or claiming your product treats it.
What Do I Do When a Patient Wants to Write a Testimonial About How PRP “Cured” Their Knee?
You cannot publish a testimonial with disease cure claims for an unapproved therapy. Ask the patient to describe their experience instead: the care they received, the staff, the consultation process. “I felt supported and well-informed throughout my visit” is compliant. “PRP cured my knee pain” is not.
Is There a Framework I Can Give My Marketing Team?
Yes. This article is that framework. Share the red/yellow/green system with your team. Before publishing any content, they should ask: is this red, yellow, or green? If unsure, treat it as red until verified.
Can I Describe What PRP Is Without Making a Claim?
Yes. “PRP stands for platelet-rich plasma. It is prepared by drawing a small sample of blood and processing it to concentrate platelets.” This is a green light process description. No treatment claim. No outcome promise.
What Happens if I Use Red Light Language and Get Caught?
FDA warning letters ask for a written response within 15 business days. FTC penalties can reach $53,088 per violation. Ad accounts get banned. Warning letters are public record and indexed by Google. In severe cases, founders can be banned from a whole line of business. In January 2025, the FTC banned the co-founders of a stem cell company from marketing stem cell treatments.
Do These Rules Apply to Social Media and Email Too?
Yes. FDA and FTC rules apply to all public marketing: websites, social media, email, Google Business Profile, video, print materials, and ads. The platform does not matter. The content does.
For more on building a compliant marketing strategy for regenerative medicine, subscribe to Oscar’s YouTube channel for weekly insights from industry leaders: https://www.youtube.com/@oatellez
Key Takeaways
- Red light means never publish. Disease cure claims, guaranteed outcomes, FDA approval misrepresentations, and exosome treatment marketing are prohibited under all circumstances.
- Yellow light requires specific framing. Research language, off-label disclosures, and patient experience statements are allowed only with disclaimers, regulatory context, and consultation CTAs.
- Green light is where your marketing should live. Education, process descriptions, consultation invitations, trust signals, and balanced risk language are safe and effective.
- The framework applies to every channel. Website, social media, email, Google Business Profile, video, and ads all carry the same rules.
- Audit everything before publishing. Six yes/no questions can catch compliance problems before they become enforcement actions.
- Compliance builds trust. Patients choose practices that sound professional and credible, not practices that make unsubstantiated promises.
Let’s Build Your Compliant Marketing Strategy
The traffic light framework is the starting point. Executing it across your website, content, social media, and SEO takes industry-specific expertise. Regen Portal’s full services are built to help regenerative medicine clinics market aggressively within the rules.
If you want help building marketing that stays inside the rules, let’s talk.
Applying a framework like this across a whole site, ad account and email programme is the slow part. Our marketing compliance service does that pass, with your counsel making the final call.
Email: hello@regenportal.com YouTube: Subscribe for weekly insights
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
